Five Reasons to Choose Adeno-associated Viruses for Gene Therapy
These small but mighty DNA delivery vehicles are revolutionizing medicine.
Gene therapy has proven to be an effective approach for treating genetic diseases, which stem from alterations in a person’s DNA. Through gene therapy, genetic material enters a person’s body and is delivered into target cells, replacing damaged or mutated DNA. One of the leading vehicles for transferring this genetic material into cells is the Adeno-associated virus (AAV), a powerful tool that makes it possible not simply to treat the symptoms of certain diseases but to impact the genetic alterations that cause them.
Read on to discover five facts about these game-changing viruses.
1. AAVs are safe
Although one usually thinks of viruses as causing illnesses, AAVs do not cause any human diseases. In addition, they have a very low cytotoxicity – they are not particularly toxic to cells – and low immunogenicity, so they provoke little immune response. This, paired with the fact that viruses have evolved to deliver DNA into cells, makes AAVs an excellent vehicle for gene therapy.
2. AAVs deliver functional genes without altering the host’s genome
The AAVs used in gene therapy lack the gene that would enable their DNA to integrate into the host cell’s DNA. This makes it possible for the DNA from an AAV used in gene therapy to impact the gene expression in the host organism, as desired, without altering the host’s genome. Additionally, the AAV genome lacks the genes required for the virus to replicate. Instead, those genes are replaced with the gene of interest that needs to be repaired or replaced in the patient. As a result, there is a very low risk of AAVs causing unwanted gene modifications.
3. AAVs persist
Genes delivered by AAVs remain in host cells in the form of episomes, non-chromosomal DNA. These episomes have been demonstrated to ensure long-term gene expression in human muscle tissue for up to ten years.
4. AAVs can enter cells in many different types of tissues
There are currently twelve serotypes of AAVs with varying cell surface receptors that allow them to attach to different types of cells. AAVs can be used in many places throughout the body including the brain, lungs, heart, liver, and muscle cells – both smooth and skeletal.
5. AAVs are effective
AAVs have been and are currently being used in 350 clinical trials worldwide for the treatment of a wide range of diseases, including inherited ones such as cystic fibrosis, hemophilia B, and muscular dystrophy, as well as acquired ones such as severe heart failure and Parkinson’s disease. And the future looks bright for AAVs, with five AAV-based gene therapies having already been approved by the FDA.
Interested in learning more about AAVs?
It is no secret that AAVs has proven to be a powerful treatment option for patients with genetic diseases. By modifying AAVs they are more efficient and better at targeting specific tissues
- Rapid lateral flow test for the detection of AAV9 capsids
- Semi-quantitative AAV titer determination in cell lysates and purified preparations
- Detection of full and empty AAV9 capsids
- get results in less than 2 hours and increase your daily sample throughput
- easy workflow & process integration
- same accuracy and reproducibility as the standard AAV2 Titration ELISAs
- A20R antibody is used as capture and detection antibody
- Mouse monoclonal
- Suitable for dot blot, ELISA and neutralization assays
- Reacts with AAV6 intact particles
- Isotype: IgG2a kappa